Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cellectar Biosciences

0.3857
+0.00862.28%
Post-market: 0.3849-0.0008-0.21%18:20 EDT
Volume:1.55M
Turnover:596.80K
Market Cap:17.77M
PE:-0.28
High:0.3950
Open:0.3900
Low:0.3744
Close:0.3771
Loading ...

Cellectar Biosciences reports strategic reprioritization, reduces headcount 60%

TIPRANKS
·
11 Dec 2024

BRIEF-Cellectar Biosciences Provides Strategic Update On Clinical Development, Pipeline Programs And Corporate Restructuring

Reuters
·
11 Dec 2024

Cellectar Biosciences Inc - Restructuring to Extend Cash Runway Into Q3 2025

THOMSON REUTERS
·
11 Dec 2024

Cellectar Biosciences Inc - to Advance Clr 121225 and Clr 121125 Into Clinic

THOMSON REUTERS
·
11 Dec 2024

Cellectar Biosciences Inc - to Pursue Strategic Options for Iopfosine I 131 Development

THOMSON REUTERS
·
11 Dec 2024

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

THOMSON REUTERS
·
11 Dec 2024

Cellectar Biosciences Inc - to Reduce Headcount by Approximately 60% by End of Q4 2024

THOMSON REUTERS
·
11 Dec 2024

Cellectar Biosciences trading halted, news pending

TIPRANKS
·
11 Dec 2024

Cellectar Biosciences transferred with Buy rating at Ladenburg

TIPRANKS
·
05 Dec 2024

BRIEF-Northstar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences For Therapeutic Radioisotope Actinium-225

Reuters
·
21 Nov 2024

Northstar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

THOMSON REUTERS
·
21 Nov 2024

Positive Buy Rating on Cellectar Biosciences Driven by Promising Iopofosine-131 Results and Strategic Advancements

TIPRANKS
·
21 Nov 2024

Cellectar Biosciences Is Maintained at Outperform by Oppenheimer

Dow Jones
·
19 Nov 2024

Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $14, Maintains Outperform Rating

MT Newswires Live
·
19 Nov 2024

Cellectar Biosciences : Oppenheimer Cuts Target Price to $12 From $14

THOMSON REUTERS
·
19 Nov 2024

Cellectar Biosciences price target lowered to $12 from $14 at Oppenheimer

TIPRANKS
·
19 Nov 2024